NIH researchers develop AI tool for personalized oncology
- On April 18, 2024, researchers from the National Institutes of Health (NIH) published a proof-of-concept study in Nature Cancer detailing a new artificial intelligence (AI) tool to match patients with the appropriate cancer drug based on their tumor RNA. The tool is called the Personalized Single-Cell Expression-Based for Treatments in Oncology...
More Articles
Tailoring medication selection with pharmacogenomic testing
In modern healthcare, pharmacogenomic assessments are helping healthcare providers determine medication selection, ensuring tailored treatment plans for everyone’s unique genetic makeup. Pharmacogenomic Testing Drug–gene...Senate Report Exposes Big Pharma’s Profiteering at Americans’ Expense
On February 6, 2024, the United States Senate's Health, Education, Labor, and Pensions (HELP) Committee published a Majority Staff Report highlighting the issue of exorbitant drug prices in the United States. It focuses on the business...A Pulse Check on Advancements in the Life Sciences, Pharma Industry
In the life sciences and pharmaceutical industry, 2023 has seen remarkable advancements and breakthroughs that hold great promise for the future of healthcare. In a recent podcast episode of the Healthcare Strategies, Senior Editor Alivia...Understanding Implications of Pharmacogenomic on Prescribing
Pharmacogenomic research explores how specific genes or genetic variations can impact drug responses and treatment outcomes. While not a standard of care, pharmacogenomic testing can significantly impact prescribing and medication safety....Understanding the Pharmaceutical Drug Development Life Cycle
While the pharmaceutical industry and its stakeholders constantly develop and advance new drugs, products, and treatments, the drug development life cycle always needs new discoveries and additions in...Phase 1 Clinical Trial Achieves Leukemia Remission in 18 Patients
In a study published in Nature on March 15, 2023, researchers achieved complete or nearly complete remission in 18 patients with KMT2A-rearranged or NPMI-mutant leukemia. The phase 1 clinical trial...Developing Clinical Trial Budgets, Considerations, and Best Practices
Despite having a high risk of failure, the clinical trial process can cost millions of dollars to complete. For clinical research organizations and sponsors, a clinical trial budget is critical in determining whether a clinical trial is...Comparing Global Pharmaceutical Markets: US, UK, and China
As the COVID-19 pandemic has progressed over the last three years, the global pharmaceutical landscape has had to evolve to keep up with growing demands. While the worldwide landscape has continued to change and grow, so have the...The Fundamentals of Animal Testing in Clinical Research
While several different approaches are used during clinical research, traditional biomedical research involving animal testing to develop new treatments and drugs may be a strategy of the past after the FDA Modernization Act 2.0 was signed...Citeline and Norstella Merger Creates $5B Pharmaceutical Technology Company
Norstella, a leading pharmaceutical solutions provider, completed its merger with Citeline earlier this month. As a result of the merger, Citeline will join Norstella’s group of brands, including...FDA Awards 19 Grants for Rare Disease Research
On October 17, 2022, the FDA announced that its Orphan Products Grants Program has awarded 19 grants and 2 contracts, amounting to over $38 million, for rare disease research. This action will...Fish Oil Supplements Associated with Risk of Atrial Fibrillation
Many vitamins and supplements are readily available over the counter for patient use. Understanding the effects of supplements on healthcare can impact and inform physician practices for more effective...Sponsored by Glooko
